Headed to Canaccord Genuity's 44th Annual Growth Conference? Our co-founder and CEO Sekar (Sek) Kathiresan will be joining a fireside chat and highlighting our pipeline progress. Join us on Tuesday, August 13. https://lnkd.in/gE3PXDSW
Verve Therapeutics
Biotechnology Research
Boston, Massachusetts 31,536 followers
We are on a mission to protect the world from cardiovascular disease.
About us
Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. In 2023, Verve was recognized as a "Best Places to Work" by the Boston Globe. Verve is headquartered in Boston, Massachusetts.
- Website
-
http://www.vervetx.com
External link for Verve Therapeutics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
201 Brookline Ave
Suite 601
Boston, Massachusetts 02215, US
Employees at Verve Therapeutics
Updates
-
Today, we announced pipeline progress and earnings from Q2 2024. Here's what you need to know: • The Heart-2 Phase 1b clinical trial of VERVE-102, a single course treatment intended to durably reduce disease-driving low-density lipoprotein cholesterol, is enrolling in the U.K. and Canada. The clinical trial application was recently cleared in Australia. • The Heart-2 and PCSK9 program data update is planned for the first half of 2025. • The Phase 1b clinical trial initiation for VERVE-201 is on track for the second half of 2024. • Strong cash position and runway expected into late 2026. For more information, read the full announcement here: https://lnkd.in/evy4dY_c
-
Ready to make your next career move to an innovative company developing #geneediting medicines for #cardiovascular disease? We are looking to add a Senior Scientist, Toxicologist to our growing team. Learn more from hiring manager Kimberly Pendino and check out the role here: https://lnkd.in/eYbaTwc7
-
-
Each year, we spend a day at Cathleen Stone Island for our annual summer outing, and it never disappoints! To feed our competitive itch, we held a corn hole competition and enjoyed the outdoor air all while enjoying our favorite snacks and refreshments. At Verve, we’re proud of the culture we’re creating.
-
-
-
-
-
+3
-
-
It’s #NationalInternDay, and we’re excited to celebrate our team of interns! At Verve, we are passionate about advancing STEM education, and we are continually inspired by the curiosity, energy and fresh perspectives that our interns bring to the program. Thank you to this talented group for your contributions; together, we are shaping the future of #cardiovascular health.
-
-
We're excited to present our new series, #VerveVocab. In this bimonthly series, Verve team members will take complex scientific concepts and vocabulary related to #cardiovascular disease, #geneediting, and beyond, and make them crystal clear. First up, let's dive into "lipid nanoparticles," or in simpler terms, LNPs!
-
It’s that time again! Join us in welcoming our latest members to the Verve team. We’re excited to have new Vervians on board to fuel our mission and bring fresh, new perspectives to the table. If you have a passion for transforming the care of #cardiovascular disease, check out our open roles and see if your goals align with ours. https://lnkd.in/euwGT56
-
Our Chief Medical Officer Fred T. Fiedorek, M.D., is heading to England to present at the HEART UK - The Cholesterol Charity 37th Annual Medical and Scientific Conference on Friday. We’re looking forward to learning from our colleagues in the #cardiovascular disease (CVD) space in regards to lipids, atherosclerosis, and more, and sharing our gene editing approach to CVD. Learn more about the event here: https://lnkd.in/eKGXK_vP
-
-
Our Co-founder and CEO Sekar (Sek) Kathiresan, M.D., looks forward to participating in BMO’s 2024 Genetic Medicines Summit next week. He will take part in a panel about #geneediting commercialization and ultimate takeaways from the industry’s first FDA-approved CRISPR/Cas9 gene-edited therapy, CASGEVY™. A live webcast will be available following the presentation and will be archived for 60 days here: https://lnkd.in/eFDgAqCA
-
-
Taiji Mizoguchi, Principal Scientist, Preclinical Pharmacology will represent Verve in Japan at the 56th Annual Scientific Meeting of Japan Atherosclerosis Society. With the theme “Deciphering Atherosclerosis from Coded Information”, Taiji will discuss the role that #genetherapy plays in creating treatments for patients living with #cardiovascular diseases.
-